Idorsia Archives -

People whose blood pressure remains stubbornly high despite current drug treatment and are at increased risk of complications

J&J, Idorsia plan filings for aprocitentan data in resistant hypertension

https://pharmaphorum.com/news/jj-idorsia-plan-filings-for-aprocitentan-data-in-resistant-hypertension/

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia

Idorsia is first to EU market with orexin insomnia drug

https://pharmaphorum.com/news/idorsia-is-first-to-eu-market-with-orexin-insomnia-drug/

A new treatment for adults with insomnia disorder has been recommended for use in Europe, giving hope to

EU regulator backs Idorsia’s Quviviq for adults with insomnia

https://pharmaphorum.com/news/eu-regulator-backs-idorsias-quviviq-for-adults-with-insomnia/

Swiss biotech Idorsia has claimed FDA approval for its first product – insomnia treatment Quviviq – setting up

Dream result for Idorsia as FDA clears its insomnia drug

https://pharmaphorum.com/news/dream-result-for-idorsia-as-fda-clears-its-insomnia-drug/

Switzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a

Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial win

https://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/

Swiss biotech Idorsia and Neurocrine Biosciences of the US have amended a deal signed last year to develop

Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug

https://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/

Idorsia